Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.
Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany.
Cardiovasc Ther. 2019 Nov 26;2019:8295054. doi: 10.1155/2019/8295054. eCollection 2019.
Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death.
Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review.
Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance.
Worldwide data showed approximately 5-8% prevalence of CAD and 10-20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18-35% of patients with CAD and 46-68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population.
CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.
动脉粥样硬化性血栓形成疾病，包括冠心病（CAD）和外周动脉疾病（PAD），可导致心血管（CV）事件，如心肌梗死、中风、肢体缺血、心力衰竭和 CV 死亡。
通过全面的文献回顾评估 CAD 和 PAD 的人文和经济负担，并确定未满足的需求。
应用相关搜索词对在线出版物数据库进行搜索。选择符合纳入/排除标准的 2010 年 1 月至 2017 年 8 月期间发表的研究；也包括指南。应用两轮筛选选择相关研究。
全球数据显示 CAD 的患病率约为 5-8%，PAD 的患病率约为 10-20%，取决于研究设计、平均年龄、性别和地理位置。REACH 登记处的数据表明，18-35%的 CAD 患者和 46-68%的 PAD 患者有一个或多个血管床的疾病。控制可改变的 CV 危险因素的药物使用因国家而异（法国比加拿大低）；他汀类药物和阿司匹林是慢性疾病患者最常用的治疗方法。随着医疗技术的进步，生存率有所提高，但需要进一步改善疾病的人文负担（即，相关残疾和生活质量）。动脉粥样硬化性血栓形成疾病的经济负担很高，预计随着生存率的提高和人口老龄化，这一负担将增加。
CAD 和 PAD 是全球范围内重大的人文和经济负担，这突显了需要新的干预措施来降低动脉粥样硬化性血栓形成疾病的发生率。
